Ibio Inc (NYSEAMERICAN:IBIO) Short Interest Up 404.0% in November

Ibio Inc (NYSEAMERICAN:IBIO) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 310,271 shares, an increase of 404.0% from the October 31st total of 61,565 shares. Based on an average daily volume of 208,376 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.4% of the company’s stock are short sold.

In other Ibio news, major shareholder Eastern Capital Ltd bought 12,000,000 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was acquired at an average cost of $0.20 per share, with a total value of $2,400,000.00. Following the purchase, the insider now owns 45,744,000 shares in the company, valued at $9,148,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Ibio (IBIO) traded up $0.00 during trading hours on Friday, hitting $0.15. 749,797 shares of the company traded hands, compared to its average volume of 695,028. Ibio has a twelve month low of $0.14 and a twelve month high of $0.56.

ILLEGAL ACTIVITY NOTICE: “Ibio Inc (NYSEAMERICAN:IBIO) Short Interest Up 404.0% in November” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/17/ibio-inc-ibio-sees-significant-growth-in-short-interest.html.

Ibio Company Profile

iBio, Inc is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company’s technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants.

Receive News & Ratings for Ibio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ibio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply